Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women

Climacteric

Volumn 13, Issue 5, 2010, Pages 433-441

  Noe G ^a   Sitruk Ware, R ^b   Zegers Hochschild, F ^c   Variano, B ^b   Montero, J C ^a   Arriagada, P ^c   Li, A ^d   Stanczyk, F Z ^d   Felix, J C ^d   Mishell Jr , D R ^d   Croxatto, H B ^a  

^a Instituto Chileno de Medicina Reproductiva   (Chile)

^b POPULATION COUNCIL   (United States)

^c CLÍNICA LAS CONDES   (Chile)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

endometrium; Postmenopausal therapy; progesterone; vaginal rings

Indexed keywords

ESTRADIOL; ESTRADIOL RECEPTOR; FEM 7; KI 67 ANTIGEN; PROGESTERONE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; FEMALE; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PELVIS PAIN SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROMA; TENSION HEADACHE; TREATMENT DURATION; UROGENITAL SYSTEM PARAMETERS; VAGINA RING; VAGINAL DISCOMFORT;

ADMINISTRATION, CUTANEOUS; CONTRACEPTIVE DEVICES, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROGESTINS; TREATMENT OUTCOME; VAGINA; WOMEN'S HEALTH;

EID: 77956155402     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.492060     Document Type: Article

References (26)

1. Sitruk-Ware R. Hormonal replacement therapy. Rev Endocr Metab Disord 2002;3:243-256
2. Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;(3):CD000402. Update in Cochrane Database Syst Rev 2009;(2):CD000402
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
4. Straczek C, Oger E, et al. for the ESTHER Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-3500
5. Scarabin P-Y, Oger E, Plu-Bureau G, on behalf of the EStrogen and ThromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432
6. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: The ESTHER Study. Circulation 2007;115:840-845
7. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-454
8. Fournier A, Fabre A, Mesrine S, Marie-Boutron-Ruault C, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260-1268
9. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor-and estradiol-treated human cancerous and noncancerous breast cells. Menopause 2005;12:468-474
10. Seeger H, Mueck A. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 2008;109:11-15.
11. Wood C, Register T, Lees C, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-134
12. Einer-Jensen N, Cicinelli E, Galatino P, Pinto V, Barba B. Uterine first pass effect in postmenopausal women. Hum Reprod 2002;17:3060-3064
13. Cicinelli E, de Ziegler D. Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus. Hum Reprod Update 1999;5: 365-372
14. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403-406
15. Zegers-Hochschild F, Balmaceda JP, Fabres C, et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum Reprod 2000;15:2093-2097
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208. Erratum in JAMA 1995;274:1676.
17. Nilsen J, Brinton RD. Impact of progestins on estrogeninduced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002;143:205-212
18. Zegers-Hochschild F, Croxatto HB, Alam V. Endometrial histology and progesterone concentration in women with ovarian failure supplemented with a progesterone vaginal ring. Report on six pregnancy cycles after oocyte donation. Presented at 12th Annual Meeting ESHRE, Maastricht,. Hum Reprod 1996;11:53, Abstr 113.
19. Diaz S, Jackanicz TM, Herreros C, et al. Fertility regulation in nursing women. VIII. Progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring. Contraception 1985;32:603-622
20. Li A, Felix JC, Yang W, et al. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. Contraception 2007;76:57-65.
21. Li A, Felix JC, Yang W, et al. Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. Fertil Steril 2008;90:872-875
22. Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal route: a comparative study. Fertil Steril 1994;62:485-490
23. Yasui T, Uemura H, Tezuka M, et al. Biological effects of hormone replacement therapy in relation to estradiol levels. Horm Res 2001;56:38-44.
24. Moyer DL, Felix JC, Kurman RJ, Cuffie CA. Micronized progesterone regulation of the endometrial glandular cycling pool. Int J Gynecol Pathol 2001;20:374-379
25. Cicinelli E, de Ziegler D, Galantino P, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 2002;187:556-560
26. Koshiyama M, Konishi I, Nanbu K, et al. Immunohistochemical localization of heat shock proteins HSP70 and HSP90 in the human endometrium: correlation with sex steroid receptors and Ki-67 antigen expression. J Clin Endocrinol Metab 1995;80:1106-12